+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Market Spotlight: Sjögren's Syndrome

  • ID: 5008192
  • Report
  • March 2021
  • Region: Global
  • 32 Pages
  • Pharma Intelligence
Definition

This Market Spotlight report covers the Sjögren’s Syndrome market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, licensing and asset acquisition deals, probability of success, and a 10-year disease prevalence forecast.
  • The publisher estimates that in 2019, there were approximately 2.26 million prevalent cases of primary Sjögren’s syndrome worldwide, and forecasts that number to increase to 2.52 million prevalent cases by 2028.
  • Primary Sjögren’s syndrome has a female predominance. Globally, the publisher estimates that in 2019, 90.41% of cases aged 15 years and over were female.
  • Evoxac, a muscarinic agonist specific to M1 receptors, and LO2A, which contains isotonic glycerol and 0.015% sodium hyaluronate, are the only approved drugs for Sjögren’s syndrome.
  • The majority of industry-sponsored drugs in active clinical development for Sjögren’s syndrome are in Phase II, with only one drug in Phase III.
  • Therapies in development for Sjögren’s syndrome focus on a wide variety of targets. The pipeline drugs for Sjögren’s syndrome are administered via the oral, intravenous, and subcutaneous routes.
  • The overall likelihood of approval of a Phase I arthritis asset is 8.4%, and the average probability a drug advances from Phase III is 80%. Drugs, on average, take 9.0 years from Phase I to approval, compared to 9.2 years in the overall autoimmune/immunology space.
  • The distribution of clinical trials across Phase I-IV indicates that the majority of trials for Sjögren’s syndrome have been in the early and mid-phases of development, with 78% of trials in Phase I-II, and only 22% in Phase III-IV.
  • The US has the highest number of Sjögren’s syndrome clinical trials globally. The UK leads the major European markets, while Japan has the top spot in Asia.
  • Clinical trial activity in the Sjögren’s syndrome space is dominated by completed trials. Novartis has the highest number of completed clinical trials for Sjögren’s syndrome, with eight trials.
  • Bristol Myers Squibb and Novartis lead the industry sponsors with the highest overall number of clinical trials for Sjögren’s syndrome.
Note: Product cover images may vary from those shown

OVERVIEWKEY TAKEAWAYSDISEASE BACKGROUND
TREATMENT
  • Dry eyes
  • Dry mouth
  • Other glandular manifestations
  • Extraglandular manifestations

EPIDEMIOLOGYMARKETED DRUGSPIPELINE DRUGS
RECENT EVENTS AND ANALYST OPINION
  • Iscalimab for Sjögren's Syndrome (January 23, 2020)
  • Multiple Drugs for Sjögren's Syndrome (October 24, 2019)

PROBABILITY OF SUCCESS
LICENSING AND ASSET ACQUISITION DEALS
  • With $3bn Viela Acquisition, Horizon Builds A Pipeline

CLINICAL TRIAL LANDSCAPE
  • Sponsors by status
  • Sponsors by phase

BIBLIOGRAPHY
  • Prescription information

APPENDIX
LIST OF FIGURES
Figure 1: Trends in prevalent cases of primary Sjögren’s syndrome, 2019–28
Figure 2: Overview of pipeline drugs for Sjögren’s syndrome in the US
Figure 3: Pipeline drugs for Sjögren’s syndrome, by company
Figure 4: Pipeline drugs for Sjögren’s syndrome, by drug type
Figure 5: Pipeline drugs for Sjögren’s syndrome, by classification
Figure 6: Iscalimab for Sjögren's Syndrome (January 23, 2020): Phase II - Primary Sjögren
Figure 7: Probability of success in the arthritis pipeline
Figure 8: Clinical trials in Sjögren’s syndrome
Figure 9: Top 10 drugs for clinical trials in Sjögren’s syndrome
Figure 10: Top 10 companies for clinical trials in Sjögren’s syndrome
Figure 11: Trial locations in Sjögren’s syndrome
Figure 12: Sjögren’s syndrome trials status
Figure 13: Sjögren’s syndrome trials sponsors, by phase
LIST OF TABLES
Table 1: Prevalent cases of primary Sjögren’s syndrome, 2019–28
Table 2: Prevalent cases of primary Sjögren’s syndrome, by gender, 2019
Table 3: Marketed drugs for Sjögren’s syndrome
Table 4: Pipeline drugs for Sjögren’s syndrome in the US
Table 5: Iscalimab for Sjögren's Syndrome (January 23, 2020)
Table 6: Multiple Drugs for Sjögren's Syndrome (October 24, 2019)
Note: Product cover images may vary from those shown